First Time Loading...

Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 262.75 USD -0.48% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. [ Read More ]

The intrinsic value of one AMGN stock under the Base Case scenario is 252.58 USD. Compared to the current market price of 262.75 USD, Amgen Inc is Overvalued by 4%.

Key Points:
AMGN Intrinsic Value
Base Case
252.58 USD
Overvaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Amgen Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AMGN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Amgen Inc

Provide an overview of the primary business activities
of Amgen Inc.

What unique competitive advantages
does Amgen Inc hold over its rivals?

What risks and challenges
does Amgen Inc face in the near future?

Has there been any significant insider trading activity
in Amgen Inc recently?

Summarize the latest earnings call
of Amgen Inc.

What significant events have occurred
in Amgen Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Amgen Inc.

Provide P/S
for Amgen Inc.

Provide P/E
for Amgen Inc.

Provide P/OCF
for Amgen Inc.

Provide P/FCFE
for Amgen Inc.

Provide P/B
for Amgen Inc.

Provide EV/S
for Amgen Inc.

Provide EV/GP
for Amgen Inc.

Provide EV/EBITDA
for Amgen Inc.

Provide EV/EBIT
for Amgen Inc.

Provide EV/OCF
for Amgen Inc.

Provide EV/FCFF
for Amgen Inc.

Provide EV/IC
for Amgen Inc.

Show me price targets
for Amgen Inc made by professional analysts.

What are the Revenue projections
for Amgen Inc?

How accurate were the past Revenue estimates
for Amgen Inc?

What are the Net Income projections
for Amgen Inc?

How accurate were the past Net Income estimates
for Amgen Inc?

What are the EPS projections
for Amgen Inc?

How accurate were the past EPS estimates
for Amgen Inc?

What are the EBIT projections
for Amgen Inc?

How accurate were the past EBIT estimates
for Amgen Inc?

Compare the revenue forecasts
for Amgen Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Amgen Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Amgen Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Amgen Inc compared to its peers.

Compare the P/E ratios
of Amgen Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Amgen Inc with its peers.

Analyze the financial leverage
of Amgen Inc compared to its main competitors.

Show all profitability ratios
for Amgen Inc.

Provide ROE
for Amgen Inc.

Provide ROA
for Amgen Inc.

Provide ROIC
for Amgen Inc.

Provide ROCE
for Amgen Inc.

Provide Gross Margin
for Amgen Inc.

Provide Operating Margin
for Amgen Inc.

Provide Net Margin
for Amgen Inc.

Provide FCF Margin
for Amgen Inc.

Show all solvency ratios
for Amgen Inc.

Provide D/E Ratio
for Amgen Inc.

Provide D/A Ratio
for Amgen Inc.

Provide Interest Coverage Ratio
for Amgen Inc.

Provide Altman Z-Score Ratio
for Amgen Inc.

Provide Quick Ratio
for Amgen Inc.

Provide Current Ratio
for Amgen Inc.

Provide Cash Ratio
for Amgen Inc.

What is the historical Revenue growth
over the last 5 years for Amgen Inc?

What is the historical Net Income growth
over the last 5 years for Amgen Inc?

What is the current Free Cash Flow
of Amgen Inc?

Financials

Balance Sheet Decomposition
Amgen Inc

Current Assets 30.3B
Cash & Short-Term Investments 10.9B
Receivables 7.3B
Other Current Assets 12.1B
Non-Current Assets 66.8B
PP&E 5.9B
Intangibles 51.3B
Other Non-Current Assets 9.6B
Current Liabilities 18.4B
Accounts Payable 18.5B
Accrued Liabilities 15.4B
Other Current Liabilities -15.5B
Non-Current Liabilities 72.5B
Long-Term Debt 63.2B
Other Non-Current Liabilities 9.4B
Efficiency

Earnings Waterfall
Amgen Inc

Revenue
28.2B USD
Cost of Revenue
-8.4B USD
Gross Profit
19.8B USD
Operating Expenses
-11.6B USD
Operating Income
8.2B USD
Other Expenses
-1.4B USD
Net Income
6.7B USD

Free Cash Flow Analysis
Amgen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

AMGN Profitability Score
Profitability Due Diligence

Amgen Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Positive Gross Profit
Exceptional ROE
76/100
Profitability
Score

Amgen Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.

AMGN Solvency Score
Solvency Due Diligence

Amgen Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Low Altman Z-Score
26/100
Solvency
Score

Amgen Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMGN Price Targets Summary
Amgen Inc

Wall Street analysts forecast AMGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMGN is 313.65 USD with a low forecast of 171.7 USD and a high forecast of 399 USD.

Lowest
Price Target
171.7 USD
35% Downside
Average
Price Target
313.65 USD
19% Upside
Highest
Price Target
399 USD
52% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AMGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AMGN Price
Amgen Inc

1M 1M
-3%
6M 6M
-6%
1Y 1Y
+8%
3Y 3Y
+10%
5Y 5Y
+70%
10Y 10Y
+189%
Annual Price Range
262.75
52w Low
214.27
52w High
324.56
Price Metrics
Average Annual Return 14.6%
Standard Deviation of Annual Returns 18.85%
Max Drawdown -19%
Shares Statistics
Market Capitalization 140.7B USD
Shares Outstanding 535 919 008
Percentage of Shares Shorted 1.96%

AMGN Return Decomposition
Main factors of price return

What is price return decomposition?

AMGN News

Other Videos

Last Important Events
Amgen Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Amgen Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Amgen Inc Logo
Amgen Inc

Country

United States of America

Industry

Biotechnology

Market Cap

140.7B USD

Dividend Yield

3.43%

Description

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 24,200 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company operates in human therapeutics segment. Its marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The firm focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.

Contact

CALIFORNIA
Thousand Oaks
1 Amgen Center Dr
+18054471000.0
http://www.amgen.com/

IPO

1983-06-17

Employees

24 200

Officers

Chairman, CEO & President
Mr. Robert A. Bradway
Executive VP & CFO
Mr. Peter H. Griffith
Executive Vice President of Operations
Mr. Esteban Santos
Executive VP & Chief Technology Officer
Dr. David M. Reese M.D.
Executive Vice President of Global Commercial Operations
Mr. Murdo Gordon
Chief Accounting Officer & VP of Finance
Mr. Matthew C. Busch
Show More
Senior VP & Chief Information Officer
Mr. Mike Zahigian
Executive VP of Research and Development & Chief Scientific Officer
Dr. James E. Bradner M.D.
Vice President of Investor Relations
Justin G. Claeys
Executive VP, General Counsel & Secretary
Mr. Jonathan P. Graham
Show Less

See Also

Discover More
What is the Intrinsic Value of one AMGN stock?

The intrinsic value of one AMGN stock under the Base Case scenario is 252.58 USD.

Is AMGN stock undervalued or overvalued?

Compared to the current market price of 262.75 USD, Amgen Inc is Overvalued by 4%.